-
Min Investment
-
$1,000
-
Offering Date
-
October 22, 2024
-
Expected Close Date
-
November 28, 2024
Company Description
We're starting by creating lab-grown human tissues for use as a better replacement for animal studies. We've already generated $5.2M in sales for various applications.
Key Deal Facts
Frontier Bio creates advanced lab-grown human tissues
Replacing animal testing with human tissues made from human cells
One day making the organ transplant waitlist obsolete with on-demand organs
~$5.2M in sales for tissues and tissue engineering services
~$3.5M funding (Angels + VCs)
NSF SBIR-Funded ($256k)
$110B Market (2023)
Management Team / Advisory Board Bios
George Church
Advisor
Victoria Gruber
Head of Translational Research
Eric Bennett
CEO
Julia Schachenhofer
Research Scientist
Sam Pashneh-Tala
CTO
Omkaar Buddhikot
Tissue Engineer
Nigel Gomes
Mechatronics Engineer
Riza Sarmiento
Office Manager
Andrew Rutter
Sr. Engineer
Zhipeng Liang
Research Scientist
Wonjae Lee
Advisor & Assistant Professor of Neurosurgery
Rami El Assal
Advisor & Investor
Ravi Belani
Advisor, Stanford Instructor, & CEO of Alchemist
Ashley Krebs
Operations Manager
Sina Moeinzadeh
Advisor & Consultant
Matthew Shore
Board Member
Louise Kirkbride
Advisor
Jaimie Shores
Advisor & Reconstructive Surgeon
Terrence McKenna
Board Member